<doc>
  <docmeta id="113hr1366ih">
    <bill congress="113" type="hr" number="1366" version="ih"/>
    <revision size="2200" annotations="0" id="5" commit-time="2013-04-09T21:41:11+00:00" committer="favila" doc="113hr1366ih/5.xml" status="complete">
      <description>Edited via AKN</description>
    </revision>
  </docmeta>
  <bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H94D0256CED8F4A31BF7AA24DE16D517D" public-private="public">
	<metadata>
<dublinCore>
<title>113 HR 1366 IH: Stop Oxy Abuse Act of 2013</title>
<publisher>U.S. House of Representatives</publisher>
<date>2013-03-21</date>
<format>text/xml</format>
<language>EN</language>
<rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>H. R. 1366</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20130321">March 21, 2013</action-date>
			<action-desc>
        <sponsor name-id="L000562">Mr. Lynch</sponsor> (for
			 himself, <cosponsor name-id="F000451">Mr. Fitzpatrick</cosponsor>,
			 <cosponsor name-id="R000395">Mr. Rogers of Kentucky</cosponsor>,
			 <cosponsor name-id="R000011">Mr. Rahall</cosponsor>,
			 <cosponsor name-id="K000375">Mr. Keating</cosponsor>,
			 <cosponsor name-id="W000672">Mr. Wolf</cosponsor>, and
			 <cosponsor name-id="S000480">Ms. Slaughter</cosponsor>) introduced the
			 following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and
			 Commerce</committee-name>
      </action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To direct the Commissioner of Food and Drugs to modify
		  the approval of any drug containing controlled-release oxycodone hydrochloride
		  to limit such approval to use for the relief of severe-only instead of
		  moderate-to-severe pain, and for other purposes.</official-title>
	</form>
	<legis-body id="H41A178E7E31B43A7BB1D76518C263D97" style="OLC">
		<section id="HCB679FDCD43B4F519BE683E881672C94" section-type="section-one">
      <enum>1.</enum>
      <header>Short title</header>
      <text display-inline="no-display-inline">This Act may be cited as the
			 <quote>
          <short-title>Stop Oxy Abuse Act of
			 2013</short-title>
        </quote>.</text>
		</section>
    <section id="H7ED4A5F555634C4C843B123EC4414191">
      <enum>2.</enum>
      <header>Limiting approval
			 of drugs containing controlled-release oxycodone hydrochloride to use for
			 relief of severe-only pain</header>
			<subsection id="H800CE6B9AFC94B4FA05919CD2892D903">
        <enum>(a)</enum>
        <header>In
			 general</header>
        <text display-inline="yes-display-inline">Not later than 90
			 days after the date of the enactment of this Act, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Commissioner of Food and
			 Drugs</cato:entity-ref> shall take such actions as may be necessaryâ€”</text>
				<paragraph id="HF494DF34D9A04D39B91F97F54830096C">
          <enum>(1)</enum>
          <text>to modify the
			 approval of any drug containing controlled-release oxycodone hydrochloride
			 under <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505">section 505 of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>)</cato:entity>
			 to limit such approval to use for the relief of severe-only instead of
			 moderate-to-severe pain; and</text>
				</paragraph>
        <paragraph id="H84A3522E7CE443C7A3A9C68D4106F0C1">
          <enum>(2)</enum>
          <text>to limit any
			 subsequent approval of a drug containing controlled-release oxycodone
			 hydrochloride under such section to use for the relief of severe-only
			 pain.</text>
				</paragraph>
      </subsection>
      <subsection id="H208310069E5B4E30850B9B40E8DE143F">
        <enum>(b)</enum>
        <header>Applicability</header>
        <text>Any
			 modification required by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Stop Oxy Abuse Act of 2013/s:2/ss:a/p:1" proposed="true">subsection (a)(1)</cato:entity-ref> shall apply to drugs introduced or
			 delivered for introduction into interstate commerce on or after the date that
			 is 180 days after the date of the enactment of this Act.</text>
			</subsection>
    </section>
  </legis-body>
</bill>
</doc>